ISSX New Investigator Group Fireside Chat with Dr. Sonia de Morais

  • Register
    • Non-member - $49
    • Member - Free!
    • Student - Free!
    • Premier - Free!

    Continue

The ISSX New Investigator Group will present a series of Fireside Chats with influential senior scientists in our field. Each chat session will be moderated by a member of the group and the discussion will include wide-ranging topics such as current scientific trends, leveraging your network, and thinking strategically about your career in industry, academia, and/or government.  

About the Speaker:

Dr. Sonia de Morais has an extensive career in research in pharmaceutical sciences both in academia and industry. Following a Bachelor of Science degree in Pharmacy from the University of Sao Paulo state in Araraquara, Brazil, Dr. de Morais gained a Master of Science degree from the University of Bath in England. She then moved to Canada where she conducted doctoral studies at the Faculty of Pharmacy at University of Toronto characterizing the impact of deficiencies in glucuronidation pathways on acetaminophen bioactivation and hepatotoxicity. Dr. de Morais continued her career with a postdoctoral research at the Medical School of the University of Toronto, in Canada, in the Department of Pharmacology and a postdoctoral fellowship at the National Institutes of Environmental Health Sciences (NIEHS) in North Carolina. Following her research at NIEHS, Dr. de Morais worked as a Research Fellow at Yale University with Dr. Jennifer Doudna, who recently won the Nobel Prize for the discovery of CRISPR. Dr. de Morais started her career in the pharmaceutical industry at Boehringer Ingelheim in Ridgefield, Connecticut in 1995. She led a team of scientists involved in in vitro drug metabolism assays and in vivo PK, in support of project teams in the Discovery and Development phases. She moved to Pfizer in 1999 and started a laboratory focused on drug transporter technology. Her role expanded beyond transporters, to include in vitro drug metabolism and safety assays as well as the development of in silico tools to support hit-to-lead projects. Dr. de Morais moved to Abbott/AbbVie laboratories in 2008 and worked in a lead DMPK role until mid-2016. Her role involved leading all DMPK functions in the North Chicago site, including in vitro high throughput and definitive assays for regulatory filings for drug metabolizing enzymes and transporters, biotransformation, bioanalysis and in vivo pharmacokinetics. Dr. de Morais has been invited to speak at many national and international events and has an extensive publication record. In July 2016, she chaired a session on drug transporters at the Drug Metabolism Gordon conference. She was also part of the International Society for the Study of Xenobiotics (ISSX) council in the role of treasurer, and Head of the Finance Committee. She departed AbbVie in 2016 and is currently working as an independent consultant for the biopharmaceutical industry.

Sonia de Morais

ISSX New Investigator Group Fireside Chat: A Conversation with Sonia de Morais, Ph.D.

Dr. Sonia de Morais has an extensive career in research in pharmaceutical sciences both in academia and industry. Following a Bachelor of Science degree in Pharmacy from the University of Sao Paulo state in Araraquara, Brazil, Dr. de Morais gained a Master of Science degree from the University of Bath in England. She then moved to Canada where she conducted doctoral studies at the Faculty of Pharmacy at University of Toronto characterizing the impact of deficiencies in glucuronidation pathways on acetaminophen bioactivation and hepatotoxicity. Dr. de Morais continued her career with a postdoctoral research at the Medical School of the University of Toronto, in Canada, in the Department of Pharmacology and a postdoctoral fellowship at the National Institutes of Environmental Health Sciences (NIEHS) in North Carolina. Following her research at NIEHS, Dr. de Morais worked as a Research Fellow at Yale University with Dr. Jennifer Doudna, who recently won the Nobel Prize for the discovery of CRISPR. Dr. de Morais started her career in the pharmaceutical industry at Boehringer Ingelheim in Ridgefield, Connecticut in 1995. She led a team of scientists involved in in vitro drug metabolism assays and in vivo PK, in support of project teams in the Discovery and Development phases. She moved to Pfizer in 1999 and started a laboratory focused on drug transporter technology. Her role expanded beyond transporters, to include in vitro drug metabolism and safety assays as well as the development of in silico tools to support hit-to-lead projects. Dr. de Morais moved to Abbott/AbbVie laboratories in 2008 and worked in a lead DMPK role until mid-2016. Her role involved leading all DMPK functions in the North Chicago site, including in vitro high throughput and definitive assays for regulatory filings for drug metabolizing enzymes and transporters, biotransformation, bioanalysis and in vivo pharmacokinetics. Dr. de Morais has been invited to speak at many national and international events and has an extensive publication record. In July 2016, she chaired a session on drug transporters at the Drug Metabolism Gordon conference. She was also part of the International Society for the Study of Xenobiotics (ISSX) council in the role of treasurer, and Head of the Finance Committee. She departed AbbVie in 2016 and is currently working as an independent consultant for the biopharmaceutical industry.

Key:

Complete
Failed
Available
Locked
ISSX New Investigator Group Fireside Chat | Dr. Sonia de Morais
Recorded 04/19/2022
Recorded 04/19/2022 Dr. Sonia de Morais has an extensive career in research in pharmaceutical sciences both in academia and industry. Following a Bachelor of Science degree in Pharmacy from the University of Sao Paulo state in Araraquara, Brazil, Dr. de Morais gained a Master of Science degree from the University of Bath in England. She then moved to Canada where she conducted doctoral studies at the Faculty of Pharmacy at University of Toronto characterizing the impact of deficiencies in glucuronidation pathways on acetaminophen bioactivation and hepatotoxicity. Dr. de Morais continued her career with a postdoctoral research at the Medical School of the University of Toronto, in Canada, in the Department of Pharmacology and a postdoctoral fellowship at the National Institutes of Environmental Health Sciences (NIEHS) in North Carolina. Following her research at NIEHS, Dr. de Morais worked as a Research Fellow at Yale University with Dr. Jennifer Doudna, who recently won the Nobel Prize for the discovery of CRISPR. Dr. de Morais started her career in the pharmaceutical industry at Boehringer Ingelheim in Ridgefield, Connecticut in 1995. She led a team of scientists involved in in vitro drug metabolism assays and in vivo PK, in support of project teams in the Discovery and Development phases. She moved to Pfizer in 1999 and started a laboratory focused on drug transporter technology. Her role expanded beyond transporters, to include in vitro drug metabolism and safety assays as well as the development of in silico tools to support hit-to-lead projects. Dr. de Morais moved to Abbott/AbbVie laboratories in 2008 and worked in a lead DMPK role until mid-2016. Her role involved leading all DMPK functions in the North Chicago site, including in vitro high throughput and definitive assays for regulatory filings for drug metabolizing enzymes and transporters, biotransformation, bioanalysis and in vivo pharmacokinetics. Dr. de Morais has been invited to speak at many national and international events and has an extensive publication record. In July 2016, she chaired a session on drug transporters at the Drug Metabolism Gordon conference. She was also part of the International Society for the Study of Xenobiotics (ISSX) council in the role of treasurer, and Head of the Finance Committee. She departed AbbVie in 2016 and is currently working as an independent consultant for the biopharmaceutical industry.
You must register to access.